• Nucleon Security

  Participated · Seed · Sep 2025

  Nucleon Security designs and deploys automated, intelligent cybersecurity solutions based on agentic AI, with a platform that spans the full defense cycle. Its product suite includes a Zero Trust endpoint detection and response (EDR) system, a sovereign managed detection and response (MDR) service, Malprob AI for advanced malware analysis, and ScorX for alert prioritization. The company already supports over 100 clients across Africa, including organizations in Tunisia, Côte d’Ivoire, Burkina Faso, Nigeria, and Madagascar. Founded in 2019 in Morocco, Nucleon aims to industrialise its agentic AI Zero Trust platform and make proactive cybersecurity accessible across the continent. The firm plans to use new capital to accelerate international expansion and deepen R&D on its Zero Trust solutions. The company positions its automation as a response to a chronic shortage of cybersecurity professionals and rising global cybercrime costs cited in the article.

• Akeso

  Participated · Series D · Nov 2019

  Akeso is a Zhongshan, China–based clinical-stage biopharmaceutical company focused on in-house discovery and development of innovative mono- and bi-specific antibody drugs for oncology and immunology. Its pipeline is centered around PD-1–targeted bispecific antibodies and includes advanced oncology candidates such as AK104 (anti-PD-1/CTLA-4), AK105 (anti-PD-1), AK112 (anti-PD-1/VEGF) and AK109 (anti-VEGFR2). In immunology the company has programs targeting autoimmune diseases, including AK101 (anti-IL12/IL23) and AK111 (anti-IL17). Led by founder and CEO Dr. Xia Yu, Akeso is pursuing clinical development of multiple candidates. The company completed a nearly US$150M Series D financing to support its plans. Akeso intends to use the funds to accelerate clinical trials, expand R&D of its innovative drug pipeline, broaden its global presence with new U.S. clinical trials, and scale manufacturing capabilities.

No current team members are available.